Joseph Cooper Honorary Secretary of the B&F A-S Soc,
... B&F A-S Soc 1871 - 79. C 92/1-108 A-Z;
1879 - Gale Group | SAS Part 1
Produção Nacional
Revisado por pares
Renata Nacasaki Silvestre, Jiří Eitler, Júlia Teixeira Cottas de Azevedo, Mariane Cariati Tirapelle, Daianne Maciely Carvalho Fantacini, Lucas Eduardo Botelho de Souza, Kamilla Swiech, Dimas Tadeu Covas, Rodrigo T. Calado, Paola Ortiz Montero, Kelen Cristina Ribeiro Malmegrim, Marxa L. Figueiredo, Torsten Tonn, Virgínia Picanço‐Castro,
Natural killer 92 (NK-92) cells are an attractive therapeutic approach as alternative chimeric antigen receptor (CAR) carriers, different from T cells, once they can ... The modest in vivo outcomes observed with NK-92 cells continue to present hurdles in successfully translating NK-92 cell therapies into clinical applications. Adoptive transfer of CAR-NK-92 cells holds out the promise of therapeutic benefit ... results yet, and further improvement of CAR-NK-92 cells is necessary.In this study, we conducted ...
Tópico(s): T-cell and B-cell Immunology
2023 - Frontiers Media | Frontiers in Immunology
1868, Foreign: Volume 92:1 Letter. From Marcus Flowers. To Harry S. Parkes. Nagasaki.
0000 - Gale Group | NCCO AsiaWest
Wenbo Nie, Xuemiao Huang, Lijing Zhao, Taiwei Wang, Dan Zhang, Tianxin Xu, Lin Du, Yuxiang Li, Weiyuan Zhang, Fengjun Xiao, Lisheng Wang,
... crucial functions in cutaneous wound healing. MiR-17-92 is a multifunctional microRNA (miRNA) cluster that plays ... aimed to explore the function of miR-17.92 in wound healing as a component of MSC- ... collected by ultracentrifugation. The levels of miR-17-92 in MSCs and MSC-Exos were determined by ... excision wounds in the skin of miR-17-92 knockout (KO) and wild-type (WT) mice. The ... antiferroptotic effects of MSC-Exos overexpressing miR-17-92 were assayed by evaluating the relative levels of angiogenic and ferroptotic markers.MiRNA-17-92 was found to be highly expressed in MSCs ...
Tópico(s): Circular RNAs in diseases
2023 - Elsevier BV | Tissue and Cell
... with Minutes of Evidence and Appendices. (Cd. 1789-92) IOR/L/PARL/2/318
0000 - Gale Group | NCCO EuropeAfrica
Fang Yang, Yanjing Wang, Hongli Zhao, Xin Huang, Yi-nan Fang, Wen-Yi Chen, Ruo-zhen Han, Ai Zhao, Jimin Gao,
... Activation Protein-Chimeric Antigen Receptor Natural killer (NK)-92 cells (hFAP-CAR-NK-92 cells) and explore their potential therapeutic effects in ... carcinoma tissue. Then the engineered hFAP-CAR-NK-92 cells efficiency was determined in vitro with lactate ... The safety and efficacy of hFAP-CAR-NK-92 cells adoptive transfer immunotherapy in a tumor-bearing ... was not significantly different between hFAP-CAR-NK-92 and NK-92 cells ( p > 0.05). The hFAP-CAR-NK-92 cells presented a higher killing efficiency against the ...
Tópico(s): Ubiquitin and proteasome pathways
2023 - Discovery Medicine | Discovery Medicine
IEEE Xplore
1868, Foreign: Volume 92:1 Letter. From R. Eusden. To Harry S. Parkes. Hakodate.
0000 - Gale Group | NCCO AsiaWest
Akhil Vaid, Isotta Landi, Girish N. Nadkarni, Ismail Nabeel,
... accuracy for shoulder pain at 0·93 (0·92–0·93) but performed similarly or slightly worse ... 89 (0·88–0·90)0·93 (0·92–0·93)0·93 (0·92–0·93)0·92 (0·91–0·93)Sensitivity0·93 (0·92–0·95)0·92 (0·90–0·93)0·87 (0·85– ... 87 (0·86–0·88)0·93 (0·92–0·94)0·96 (0·95–0·97) ... 93–0·94)0·91 (0·90–0·92)Sensitivity0·86 (0·84–0·89)0·91 ( ... 95)0·97 (0·96–0·97)0·92 (0·91–0·93)Knee painAccuracy0·90 (0· ... 89 (0·88–0·91)0·93 (0·92–0·94)0·92 (0·91–0·94) ...
Tópico(s): Text Readability and Simplification
2023 - Elsevier BV | The Lancet Digital Health
Volume 92
0000 - Gale Group | NCCO BritishPolitics
Lydia T Navarrete-Galvan, Michael Guglielmo, Judith Cruz Amaya, Julie Smith‐Gagen, Vincent C. Lombardi, Rebecca Merica, Dorothy Hudig,
Abstract Background The NK cell line NK-92 and its genetically modified variants are receiving attention as immunotherapies to treat a range of malignancies. However, since NK-92 cells are themselves tumors, they require irradiation prior ... by patients’ immune systems. Here, we investigated NK-92 cell-mediated serial killing for the effects of ... of the death receptor Fas (CD95), and NK-92 cell susceptibility to attack by activated primary blood ... used 51 Cr-release assays with low NK-92 effector cell to target Raji, Daudi or K562 ...
Tópico(s): T-cell and B-cell Immunology
2022 - BioMed Central | Journal of Translational Medicine
IEEE Xplore
... with Minutes of Evidence and Appendices. (Cd. 1789-92) IOR/L/PARL/2/318
0000 - Gale Group | NCCO EuropeAfrica
Fangming Wang, Liyuan Wu, Le Yin, Hui Shi, Yuchun Gu, Nianzeng Xing,
The chimeric antigen receptor NK-92 (CAR NK-92) cell targeting the prostate-specific membrane antigen (PSMA) has shown antitumour effects in castration-resistant prostate cancer (CRPC). ... PD-L1) and its mechanisms on CAR NK-92 and CRPC cells and the effect of the ... mAb) on PD-L1 expressed on CAR NK-92 cells remain unknown.Human dendritic cells and CD8+ ... anti-PD-L1/PD-1 mAb, CAR NK-92 or cocultured CD8+ T cells.Significantly upregulated expression ... observed in cocultured C4-2 and CAR NK-92 cells. In addition, upregulation of PD-L1 expression ...
Tópico(s): Immunotherapy and Immune Responses
2022 - Springer Science+Business Media | Clinical and Translational Medicine
IEEE Xplore
... with Minutes of Evidence and Appendices. (Cd. 1789-92) IOR/L/PARL/2/318
0000 - Gale Group | NCCO EuropeAfrica
Gils Roex, Diana Campillo-Davó, Donovan Flumens, Philip Anthony Gilbert Shaw, Laurens Krekelbergh, Hans De Reu, Zwi Berneman, Eva Lion, Sébastien Anguille,
... in the form of the clinically validated NK-92 cell line.Given our goal to develop a ... the functionality of mRNA-engineered dual-CAR NK-92 against tumor B-cell lines and primary patient ... proliferative rate and functionality of dual-CAR NK-92 cells was investigated.Co-electroporation of CD19 and ... efficient, resulting in 88.1% dual-CAR NK-92 cells. In terms of CD107a degranulation, and secretion ... IFN)-γ and granzyme B, dual-CAR NK-92 significantly outperformed single-CAR NK-92. More importantly, the killing capacity of dual-CAR ...
Tópico(s): Nanowire Synthesis and Applications
2022 - BioMed Central | Journal of Translational Medicine
1868, Foreign: Volume 92:1 Letter. From Harry S. Parkes. To A. B. Mitford Esqre. Yokohama.
0000 - Gale Group | NCCO AsiaWest
Silvia Méndez‐Flores, Ángel A. Priego‐Ranero, Daniel Azamar‐Llamas, Héctor Olvera‐Prado, Kenia Ilian Rivas‐Redonda, Eric Ochoa‐Hein, Andric Pérez-Ortíz, Mario Enrique Rendón‐Macías, Estefano Rojas‐Castañeda, Said Urbina‐Terán, Luis Septién‐Stute, Thierry Hernández‐Gilsoul, Adrián Andrés Aguilar‐Morgan, Dheni A. Fernández‐Camargo, Elizabeth Olivares‐Martínez, Diego F. Hernández‐Ramírez, Gonzalo Torres‐Villalobos, Janette Furuzawa‐Carballeda,
... 29.4–137.5 87.9 ± 30.2 92.0 29.4–135.1 87.3 ± 20. ... 4.0) .7257 pSO2; mean ± SD Median IQR 92 ± 2.5 92.0 –91 to 94 93 ± 2.0 93 –91 to 95 92 ± 2.9 92 –91 to 93 Leukocyte count (×103/μl), mean ± ... administration, the patient percentage with oxygen saturation readings ≥92% in the PTIC and placebo groups were 90% ... mean ± SD Median IQR 94 ± 2.4 94 92–95 93 ± 3.3 93 91–95 95 ± ... 7 95 93–96 93 ± 2.2 93 92–95 95 ± 2.1 95 93–97 95 ± ... The Kaplan–Meier survival curve for oxygen saturations ≥92% while breathing ambient air was statistically different between ...
Tópico(s): Long-Term Effects of COVID-19
2022 - Springer Science+Business Media | Clinical and Translational Medicine
... 36-55;-(5) Negotiations for Peace. ff. 56-92;-(6) Const
0000 - Gale Group | NCCO EuropeAfrica
Kellsye P. Fabian, James W. Hodge,
... NK cell therapy as cancer treatment. The NK-92 cell line has been successfully modified to express ... or prior exposure to the tumor antigens, NK-92 provides an opportunity for the development of next- ... the-shelf cell therapy platforms. CAR-engineered NK-92 cells have demonstrated robust antitumor activity in in ... studies, propelling the clinical development of CAR NK-92 cells. Preliminary phase 1 data indicate that CAR NK-92 can be safely administered in the clinic. In ... NK cell therapy as cancer treatment. The NK-92 cell line has been successfully modified to express ...
Tópico(s): T-cell and B-cell Immunology
2021 - Elsevier BV | Molecular Therapy — Oncolytics
... with Minutes of Evidence and Appendices. (Cd. 1789-92) IOR/L/PARL/2/318
0000 - Gale Group | NCCO EuropeAfrica
Kimberly H. Nguyen, Kimchi Nguyen, Megan Geddes, Jennifer D. Allen, Laura Corlin,
... 89.2, 91.6)91.1(90.1, 92.2)92.8(92.1, 93.6)94.2(93.5, 94. ... 77.2, 83.1)91.0(89.7, 92.4)94.6(93.2, 95.9)94.4(92.6, 96.2)95.7(94.3, 97. ... 89.7)90.8(90.2, 91.3)92.0(91.6, 92.5)92.3(91.8, 92.7)*p-value for trend from April to ... 3, 28.9)0.88(0.84, 0.92)COVID-19 Status Previously diagnosed with COVID-1957. ...
Tópico(s): COVID-19 epidemiological studies
2021 - Elsevier BV | American Journal of Infection Control